Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas W Fischer

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
JCI Insight|August 10, 2018
Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activityNicholas W Fischer, Aaron Prodeus, Jean Gariépy
Cell Cycle (Georgetown, Tex.)|November 5, 2016
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosisNicholas W Fischer, Aaron Prodeus, David Malkin, et al.
Journal of the National Cancer Institute|June 23, 2023
Emerging insights into ethnic-specific TP53 germline variantsNicholas W Fischer, Yu-Heng Vivian Ma, Jean Gariépy
Journal of the National Cancer Institute|June 30, 2018
Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni SyndromeNicholas W Fischer, Aaron Prodeus, James Tran, et al.
Molecular Therapy. Nucleic Acids|April 29, 2015
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated CancersAaron Prodeus, Aws Abdul-Wahid, Nicholas W Fischer, et al.
International Journal of Cancer|May 15, 2018
Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cellsAws Abdul-Wahid, Marzena Cydzik, Nicholas W Fischer, et al.
Molecular Therapy. Nucleic Acids|September 10, 2018
A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In VivoAaron Prodeus, Amanda Sparkes, Nicholas W Fischer, et al.
The Oncologist|October 22, 2024
Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapyAnnamaria Ruzzo, Francesco Graziano, Silvia Palladino, et al.
JCI Insight|September 22, 2017
VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responsesAaron Prodeus, Aws Abdul-Wahid, Amanda Sparkes, et al.
Nature Communications|September 29, 2025
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroupNicholas W Fischer, Noel Ong, Brianne Laverty, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
JCI Insight|August 10, 2018
Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activityNicholas W Fischer, Aaron Prodeus, Jean Gariépy
Cell Cycle (Georgetown, Tex.)|November 5, 2016
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosisNicholas W Fischer, Aaron Prodeus, David Malkin, et al.
Journal of the National Cancer Institute|June 23, 2023
Emerging insights into ethnic-specific TP53 germline variantsNicholas W Fischer, Yu-Heng Vivian Ma, Jean Gariépy
Journal of the National Cancer Institute|June 30, 2018
Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni SyndromeNicholas W Fischer, Aaron Prodeus, James Tran, et al.
Molecular Therapy. Nucleic Acids|April 29, 2015
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated CancersAaron Prodeus, Aws Abdul-Wahid, Nicholas W Fischer, et al.
International Journal of Cancer|May 15, 2018
Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cellsAws Abdul-Wahid, Marzena Cydzik, Nicholas W Fischer, et al.
Molecular Therapy. Nucleic Acids|September 10, 2018
A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In VivoAaron Prodeus, Amanda Sparkes, Nicholas W Fischer, et al.
The Oncologist|October 22, 2024
Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapyAnnamaria Ruzzo, Francesco Graziano, Silvia Palladino, et al.
JCI Insight|September 22, 2017
VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responsesAaron Prodeus, Aws Abdul-Wahid, Amanda Sparkes, et al.
Nature Communications|September 29, 2025
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroupNicholas W Fischer, Noel Ong, Brianne Laverty, et al.
Pageof 2